IBMC
ibmc01 ibmc02 ibmc03 ibmc04 ibmc05 ibmc06 ibmc07 ibmc08 ibmc09 ibmc10 ibmc11 ibmc12
jQuery Image Slider by WOWSlider.com v2.0
web del Instituto de Biología Molecular y Celular
Dra. Isabel Martinez-Lacacy

Unit: Molecular Diagnostic and Therapies
Subunit: Molecular and Cellular Oncology
Group: Chemoresistance to antineoplasic drugs
Category: Investigator
Phone: + 34 966 65 84 77
Email: imlacaci@umh.es
Degree: Biology
Ph.D program: PhD degree with Honors, Georgetown University, Washington, DC, USA (Director: Prof. Robert B. Dickson), 1995.
Postdoctoral positions: Postdoctoral fellow at the Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Studies of regulation of growth factors and receptors in mammmary epithelial and breast cancer cells.(Prof. David S. Salomon) 1995-1999.
Previous positions:
1. Research Associate at the Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 1999-2003.
2. "Ramón y Cajal" Investigator at the Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante), Spain. 2003-2008.
Current Position: Associate Professor of Biochemistry and Molecuar Biology (Since 2008).
Research Fields:
1. Studies of molecular mechanisms of action of potential antineoplasic drugs through the study of signal transduction mechanisms linked to cell cycle regulation.
2. Identificaction of novel molecular targets through pharmacogenomic and pharmacoproteomic studies.
3. Validation of tyrosine kinase inhibitors as novel antitumor agents in cancer.
4. Chemoresistance and antineoplasic drugs.
Representative Publications:

  • Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis Still an Unresolved Question. M.P. Menéndez-Gutiérrez, J.A. Ferragut, M.P. García-Morales, I. Martinez-Lacaci and M. Saceda. Mol. Cancer Ther. 2010. Mol. Cancer Ther. 9, 2441-2442.
  • Inhibition of Hsp90 function by ansamycins causes dowregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines. P. García-Morales, E. Carrasco-García, P. Ruiz-Rico, R. Martínez-Mira, M.P. Menéndez-Gutierrez, J.A. Ferragut, M. Saceda and I. Martínez-Lacaci. 2007. Oncogene 26, 7185-7193.
  • Cyclin D3 is downregulated by rapamycin in HER2 overexpressing breast cancer cells. P. García-Morales, E. Hernando, E. Carrasco-García, M.P. Menéndez-Gutierrez, M. Saceda and I. Martínez-Lacaci. 2006. Mol. Cancer Ther. 5, 2172-2181.
  • Ras Transformation Causes Sustained Activation of the EGFR and Elevation of MAPK in Human Mammary Epithelial Cells. I. Martínez-Lacaci, S. Kannan, M. De Santis, C. Bianco, N. Kim, B. Wallace-Jones, A. Ebert, C. Wechselberger and D.S. Salomon. 2000. Int. J. Cancer 88, 44-52.
  • Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. I. Martínez-Lacaci, M. Saceda, G.D. Plowman, G.R. Johnson, N. Normanno, N., D.S. Salomon and R.B. Dickson. 1995. Endocrinol. 136, 3983-3992.